Skip to main content
. 2020 Dec 7;12(12):3760. doi: 10.3390/nu12123760

Figure 2.

Figure 2

The 28-day mortality from randomization (day 1) to day 28 in a trial of high-dose intravenous vitamin C (HDIVC) in patients with COVID-19. Kaplan–Meier analysis was used to estimate the 28-day mortality and survival curves were compared with the Wilcoxon test (p = 0.05) among severe COVID-19 patients (baseline SOFA score ≥ 3). Cox regression was used as multiple comparisons (HR, 0.32 (95%CI, 0.10–1.06); p = 0.06). HDIVC—high-dose intravenous vitamin C. Reproduced with permission from Zhang J. et al. [82].